Background: The use of proton pump inhibitors has been associated with an increased risk
of hip fracture. We sought to further explore the relation between duration of exposure to …

A large Canadian cohort was studied over 10 years to see if proton pump inhibitor (PPI) use
increased the risk of sustaining a fragility fracture. We found an increased risk of fracture in …

Previous studies evaluated the association between proton pump inhibitor (PPI) use and
subsequent fracture risk, but they showed ambiguous results. Therefore, the objective was to …

To identify the relationship between proton-pump inhibitors (PPIs) and the risk of fracture, we
conducted an update meta-analysis of observational studies. Results showed that PPI use …

We performed a meta-analysis of relevant studies to quantify the magnitude of the
association between proton pump inhibitors (PPIs) and risk of hip fracture. Patients with PPIs …

Background Concerns have been raised about the risk of fractures with acid-suppressive
medications, such as proton pump inhibitors and histamine 2-receptor antagonists. Methods …

OBJECTIVES: Proton pump inhibitor (PPI) use has been identified as a risk factor for hip and
vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis …

Proton pump inhibitors (PPIs) are associated with risk for fracture in osteoporotic adults. In
this population-based study, we found a significant association between PPIs and fracture in …

OBJECTIVES: Proton pump inhibitors (PPIs) are widely used in several acid-related
gastrointestinal disorders. In vivostudies have suggested that gastric suppression by PPIs …

Background This study's objective was to evaluate the association between proton-pump
inhibitor (PPI) use and bone fracture incidence and bone mineral density (BMD) by meta …